KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 74 filers reported holding KALA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $128,379 | -8.9% | 18,935 | +0.8% | 0.00% | -50.0% |
| Q3 2020 | $140,918 | -28.6% | 18,789 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $197,472 | +83.9% | 18,789 | +53.8% | 0.00% | 0.0% |
| Q1 2020 | $107,361 | -9.8% | 12,214 | +62.6% | 0.00% | +100.0% |
| Q1 2018 | $119,000 | – | 7,511 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |